Related Experiment Video

Updated: Feb 27, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.6K

Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the

Chen Wang1, Xing Zhou2, Wentao Li1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Department of Orthopaedics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210023, PR China.

Cancer Letters
|June 24, 2017
PubMed

Insights

Targeting macrophage migration inhibitory factor (MIF) shows promise for osteosarcoma treatment. Inhibiting MIF reduces tumor growth and metastasis, enhancing chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • The tumor microenvironment is crucial in osteosarcoma (OS) development.
  • Cytokine immunotherapy presents a novel treatment strategy for OS.
  • Macrophage migration inhibitory factor (MIF) is an important cytokine in OS progression.

Purpose of the Study:

  • To investigate the role of MIF in osteosarcoma progression.
  • To explore the anti-tumor effects of targeting MIF in OS.
  • To evaluate MIF's impact on the RAS/MAPK pathway and chemotherapy sensitivity.

Main Methods:

  • Analysis of MIF levels in OS patient tissues and serum.
  • In vitro studies on MIF's effect on OS cell proliferation and migration.
  • In vivo experiments using mouse xenograft and orthotopic models.
  • Assessment of MIF inhibition's effect on chemotherapy sensitivity.

Main Results:

  • MIF levels were significantly elevated in OS patients and correlated with tumor size, metastasis, and survival.
  • MIF activated the RAS/MAPK pathway, promoting OS cell proliferation and migration.
  • Targeting MIF with shRNA inhibited tumor growth and lung metastasis in vivo.
  • MIF inhibition enhanced the sensitivity of OS cells to cisplatin and doxorubicin.

Conclusions:

  • MIF plays a significant role in osteosarcoma progression.
  • Targeting MIF via immunotherapy, potentially by blocking the RAS/MAPK pathway, is a promising therapeutic strategy for OS.
  • Combined MIF inhibition and chemotherapy may improve treatment outcomes for osteosarcoma patients.
Keywords:
Lung metastasisMacrophage migration inhibitory factorOsteosarcomaRAS/MAPK pathwayTumour growth

More Related Videos

Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells08:47

Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells

Published on: August 21, 2012

17.8K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K